Greywolf Therapeutics
Kris Clark is a seasoned professional in the field of biology, currently serving as the Head of Biology at Greywolf Therapeutics since March 2023. Prior to this role, Kris held the position of Director of Kinase Biology at Exscientia from September 2021 to February 2023, and served as Principal Scientist at Sygnature Discovery from February 2016 to September 2021, where oversight of integrated drug discovery projects and development of pre-clinical candidates were key responsibilities. Kris has extensive experience leading research teams and managing diverse projects in areas such as immuno-oncology and neuroscience while delivering complex assays and biomarkers. Academic contributions include independent research at the MRC Protein Phosphorylation and Ubiquitylation Unit and various fellowships, culminating in a PhD in Medical Sciences from Radboud University Nijmegen. Kris's background also includes work at the Netherlands Cancer Institute and collaborative efforts with the biotech industry.
This person is not in any teams
Greywolf Therapeutics
Many cancers and other diseases are caused, or resist treatment, because T cells can't recognize or target cells correctly. We're progressing first-in-class antigen modulators through the clinic, developed to treat disease by controlling T cell activation. Our technology modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system. This approach marks a fundamental shift in how we treat people living with autoimmune disorders, cancers and infectious diseases.